Clinical study of deoxyribonucleotidum for adjuvant treatment of pulmonary tuberculosis with hepatic lesion.
- Author:
Yong-hao CHEN
1
;
Zhi-cheng CHEN
;
Qing-xin CHEN
;
Qing-yu LIN
Author Information
- Publication Type:Journal Article
- MeSH: Adjuvants, Immunologic; administration & dosage; therapeutic use; Adult; Alanine Transaminase; metabolism; Antitubercular Agents; adverse effects; therapeutic use; Aspartate Aminotransferases; metabolism; CD3 Complex; immunology; CD8-Positive T-Lymphocytes; cytology; drug effects; immunology; Chemical and Drug Induced Liver Injury; Deoxyribonucleotides; administration & dosage; therapeutic use; Female; Humans; Immunoglobulin A; blood; Immunoglobulin G; blood; Immunoglobulin M; blood; Injections; Liver Diseases; blood; drug therapy; Male; Middle Aged; Treatment Outcome; Tuberculosis, Pulmonary; blood; drug therapy
- From: Journal of Southern Medical University 2006;26(7):1044-1046
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate of therapeutic efficacy of deoxyribouncleotidum on pulmonary tuberculosis.
METHODSEighty patients with pulmonary tuberculosis sustaining hepatic lesion after treatment with antituberculosis drugs were randomized into therapeutic group and control group. Patients in the control group received regular treatment and those in the therapeutic group had additional deoxyribouncleotidum injection.
RESULTSALT, AST, ALP and TBIL levels were significantly higher in the therapeutic group than in the control group 4 weeks after treatment. IgG, IgA, IgM levels, and CD3(+) and CD8(+) lymphocytes were significantly increased in the therapeutic group after treatment (P<0.05).
CONCLUSIONdeoxyribouncleotidum can improve hepatic function and immunity in patients with pulmonary tuberculosis.
